Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.
How this was made
The 30-second read
Why it matters
Traders can update CHRS models using the disclosed LOQTORZI revenue guidance range, operating expense guidance, cash balance and runway, and the status of multiple clinical cohorts that feed into upcoming October and fall 2026 catalysts.
Market read
The call updates revenue guidance, cost structure expectations, cash runway, and specific clinical enrollment maturity ahead of near-term data readouts.
What to watch
Cash runway is described as sufficient through 2027, but the call also highlights legacy liability settlement dynamics and a Q2 miss of UDENYCA earn-out milestones, which could affect perceived risk and future cash flows.
Background
This is a Q2 2026 earnings call transcript for Coherus Oncology following its biosimilar business divestiture, with management emphasizing LOQTORZI growth and clinical data maturation.
Ticker impact
Coherus Oncology reported Q2 LOQTORZI net revenue of $13.6M, guided full-year LOQTORZI revenue to $57M-$62M, and updated clinical enrollment timelines.
Moderate near-term volatility is likely around the October data readout and any follow-through on LOQTORZI adoption and earn-out milestone resolution.
Key disclosed datapoints include LOQTORZI sequential growth, full-year guidance range, cash runway through 2027, and specific enrollment status for tagmokitug/casdozokitug, plus a disclosed miss of UDENYCA earn-out milestones in Q2.
Market effects
Reinforces the competitive and adoption dynamics for oncology immunotherapy and biosimilar divestiture legacy cost structures in small-cap biotech.
No clear regional market linkage beyond typical US small-cap biotech sentiment.
Limited, as the disclosed catalysts are company-specific clinical timelines and product adoption metrics.
Counterpoint
The guidance and enrollment progress may not translate into durable commercial traction if LOQTORZI faces faster-than-expected competitive substitution or if October readouts show weaker benefit than implied by enrollment maturity.
Key entities
- companyCoherus Oncology, Inc.
Subject of the earnings call transcript, providing Q2 financials, full-year guidance, cash runway, and clinical enrollment/readout timelines.
- productLOQTORZI
Company’s oncology therapy discussed with Q2 net revenue and full-year sales targets.
- clinical_programtagmokitug
Multiple cohorts (HNSCC, CRC, GI adenocarcinoma, ESCC) with enrollment status and expected data timing.
- clinical_programcasdozokitug
Phase 2 HCC study enrollment status and a planned combination study initiation in fall 2026.
- productUDENYCA
UDENYCA earn-out milestones were missed in Q2 per management, with eligibility for achievement in Q3.
